Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting

  
    
  
  
    
      Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data 
      from a Phase II clinical trial demonstrating that its ultra rapid acting 
      intranasal insulin was both superior to usual therapy (oral 
      anti-diabetic medicines and/or basal insulin) and non-inferior to 
      insulin aspart (NovoLog®), 
      a rapid-acting injectable insulin, in maintaining glucose control at 
      both 60 and 90 minutes following a meal. The data also demonstrated a 
      statistically significant reduction in the incidence of hypoglycemia 
      (low blood sugar